<DOC>
	<DOC>NCT00172068</DOC>
	<brief_summary>Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases. This open-label study will investigate the safety and efficacy of zoledronic acid in patients with breast cancer and minimal residual disease in the bone marrow.</brief_summary>
	<brief_title>Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm, Residual</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients, with primary breast cancer who had undergone complete primary tumor resection and axillary lymph node dissection Evidence of minimal residual disease (disseminated tumor cells in bone marrow) Patients had to receive one of the following adjuvant therapy categories: chemotherapy Â± hormonal therapy or hormonal therapy alone Inflammatory, metastatic or recurrent breast cancer or a history of breast cancer prior to the currently diagnosed case Neoadjuvant chemotherapy, neoadjuvant hormonal therapy, or neoadjuvant radiotherapy Prior stem cell rescue/bone marrow transplant History of other cancers aside from nonmelanomatous skin cancer or carcinoma in situ of the uterine cervix Additional protocoldefined inclusion / exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Primary breast cancer</keyword>
	<keyword>Bone metastases</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Bisphosphonates</keyword>
</DOC>